NASDAQ$NAMS
NewAmsterdam Pharma Company NV · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
NewAmsterdam Pharma reported a net loss of $39.0 million for the second quarter of 2024.
The company recognized $2.3 million in revenue during the quarter, primarily from its license agreement with Menarini. Operating expenses totaled $54.9 million, driven by research and development costs of $38.4 million and selling, general and administrative expenses of $16.5 million. Cash and cash equivalents stood at $430.7 million as of June 30, 2024.
- Revenue increased to $2.3 million from $1.7 million in Q2 2023 due to higher recognition of deferred revenue from the Menarini License.
- Net loss widened slightly to $39.0 million compared to $38.3 million in the prior-year quarter.
- Research and development expenses rose 12% year-over-year to $38.4 million, reflecting ongoing Phase 3 clinical trials.
- Cash position strengthened to $430.7 million following the February 2024 equity offering and warrant exercises.
Headline financials
Revenue & EPS history
NewAmsterdam Pharma · Revenue · Quarterly
$2.28M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
+1.2%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.6%
Avg return
30 days after
61%
11 / 18 earnings
Positive
+18.2%
Q3 2024
Best reaction
-9.6%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q2 2025 | +8.7% | — | — | |
| Q1 2026 | +1.2% | +25.4% | +1.5% | |
| Q4 2025 | -3.0% | +2.6% | -17.9% | |
| Q3 2025 | +4.3% | +6.7% | -3.5% | |
| Q1 2025 | +1.2% | -8.3% | -3.2% | |
| Q4 2024 | +10.2% | +13.4% | +21.7% | |
| Q3 2024 | +18.2% | +28.4% | -4.2% | |
| Q1 2024 | -9.6% | -12.1% | -7.8% | |
| Q2 2023 | -5.7% | -4.9% | -2.4% | |
| Q4 2023 | -5.7% | -4.9% | -2.4% | |
| Q1 2023 | +0.3% | +2.0% | -0.9% | |
| Q4 2022 | +2.1% | +1.7% | +7.4% | |
| Q3 2022 | -0.1% | +0.1% | +0.8% | |
| Q2 2022 | +0.1% | +0.1% | +0.4% | |
| Q1 2022 | +0.0% | +0.1% | +0.3% | |
| Q3 2021 | -0.3% | +0.2% | -0.1% | |
| Q2 2021 | +0.2% | +0.2% | -1.2% | |
| Q1 2021 | +0.1% | +0.2% | +1.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro